Minirin Spray (Desmopressin Acetate Trihydrate)

Desmopressin acetate mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This triggers a cascade that inserts aquaporin‑2 channels into the cell surface, allowing more water to be reabsorbed, concentrating urine. In the vascular endothelium it also promotes release of factor VIII and von Willebrand factor, aiding haemostasis.

The dose of Minirin Spray is individualized by the prescribing clinician based on the specific indication, severity of symptoms, patient age, renal function, and concurrent medications. The prescriber will set the number of sprays per dose and the interval between doses, and may adjust it during follow‑up based on clinical response and laboratory monitoring.

Safety data for desmopressin nasal spray in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women, and discuss alternative options when appropriate.

To order Minirin Spray, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Minirin Spray delivers desmopressin via the nasal route, offering rapid absorption and convenient dosing for patients who may have difficulty swallowing tablets. Oral desmopressin formulations are also available but can have variable bioavailability. Intravenous vasopressin provides immediate effect in critical care but requires hospital administration. The nasal spray balances efficacy with ease of outpatient use.

Minirin Spray should be stored at room temperature, below 25 °C, in its original packaging. Protect the device from moisture, direct sunlight and extreme temperature fluctuations. Do not refrigerate or freeze the spray, and keep the nozzle clean to maintain dose accuracy.

The spray is administered intranasally. The patient should gently blow the nose, tilt the head slightly forward, and insert the nozzle into one nostril. Press the actuator to deliver the prescribed number of sprays, then repeat in the other nostril if directed. Avoid blowing the nose for several minutes after dosing to ensure optimal absorption.

The most serious risks include severe hyponatremia, which can lead to seizures, cerebral edema, or coma, and water intoxication from excessive fluid intake. Patients should be monitored for sudden changes in mental status, severe headache, nausea, or vomiting, and serum sodium levels should be checked regularly, especially in the elderly or those with renal impairment.

Minirin Spray is contraindicated in patients with known hypersensitivity to desmopressin or any component of the formulation, in individuals with existing hyponatremia, severe renal impairment, or uncontrolled hypertension. Caution is also advised for patients taking other antidiuretic agents or medications that predispose to low sodium levels.